NEW YORK, May 13, 2021 /PRNewswire/ Â Pomerantz LLP is investigating claims on behalf of investors of
 BELLUS Health Inc. ( BELLUS or the Company ) (NASDAQ: BLU). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether BELLUS Lidar and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.Â
- Advertisement -
On July 6, 2020, Bellus provided investors with an update regarding its product BLU-5937 , in development as a treatment for chronic cough. Bellus announced that the drug had failed a Phase 2 study of chronic cough patients for whom other treatments had not worked.  Specifically, BLU-5937 was not significantly better than a placebo at reducing the frequency at which patients coughed.Â